The American Academy of Allergy, Asthma and Immunology calls off its 2020 Annual Meeting due to coronavirus concerns
March 10, 2020Medical Communications, Research and Development Big Pharma, allergy, america, asthma, immunology
The American Academy of Allergy, Asthma and Immunology (AAAAI) has called off its 2020 Annual Meeting that was schedule to …
Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype
March 10, 2020Manufacturing and Production, Sales and Marketing Boehringer, FDA, ofev, pharma
The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment of chronic fibrosing interstitial lung …
Anti-HIV drug PrEP has 30% lower concentration levels in pregnant African adolescents and young women
March 10, 2020Manufacturing and Production AIDS, HIV, PrEP, PrEP HIV, insulin
Pregnant African adolescents and young women who took the HIV drug PrEP were found to have 30% lower levels of …
Fast-acting mealtime insulin approved for children with diabetes in Canada
March 10, 2020Manufacturing and Production Type 1 diabetes, diabetes, insulin, insulin pump, type 2 diabetes
Health Canada has approved Novo Nordik’s Fiasp, a faster acting mealtime insulin, for children aged 2 and above with type …
Alligator Bioscience hires Chief Financial Officer in interim capacity
March 9, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alligator Bioscience, pharma
Andreas Johannesson has been announced as Alligator Bioscience’s new interim Chief Financial Officer (CFO), replacing ex-CFO Per-Olof Schrewelius who it …
Dr Lars Nieba appointed interim Chief Executive Officer at Nordic Nanovector
March 9, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Nordic Nanovector has appointed Dr Lars Nieba as the interim Chief Executive Officer. He is currently the company’s Chief Technology …
Chris Thatcher to step down as President and CEO of Neuronetics
March 9, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Neuronetics, Inc and Chris Thatcher, the President and CEO, have mutually agreed that he will step down from his positions …
Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts
March 9, 2020Manufacturing and Production, Medical Communications Biogen, Takeda, coronavirus, pharma
Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names …
ACC.20 cancelled due to coronavirus fears
March 9, 2020Manufacturing and Production, Medical Communications cardio, cardiology, cardiovascular
The American College of Cardiology has cancelled its upcoming ACC.20 event with the World Congress of Cardiology due to concerns …
The need for evolution in pharmacovigilance
March 9, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, pharmacovigilance
Pharmacovigilance is a critical function in ensuring public health, but is our current system built to tackle the challenges of …
UK Government outlines emergency measures to tackle coronavirus
March 9, 2020Sales and Marketing British Coronavirus, Chinese Coronavirus, Wuhan Coronavirus, coronavirus
The British Government has outlined its emergency legislation to tackle coronavirus in which people could leave work to become volunteers …
FDA authorises first therapy to tackle cortisol overproduction in Cushing’s disease
March 9, 2020Sales and Marketing Cushing's disease, FDA, pharma
The FDA has moved to approve its first therapy to directly treat the overproduction of the hormone cortisol which is …
Coronavirus forcing Eli Lilly employees to work from home
March 9, 2020Sales and Marketing Chinese Coroanvirus, Eli Lilly, Eli Lilly Coronavirus, Wuhan Coronavirus, coronavirus
Eli Lilly is asking some of its employees to work from home to stop the spread of coronavirus on its …
Uganda finalising clinical trials on new injectable HIV drug
March 9, 2020Sales and Marketing AIDS, HIV, Uganda HIV, Uganda HIV/AIDS, uganda
Uganda is preparing to enter the final stages of developing a new HIV treatment to reduce stigma and discrimination of …
NICE shoots down Dupixent for severe asthma
March 9, 2020Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …
Top Ten most popular articles on Pharmafile.com this week
March 6, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chinese Coronavirus, Wuhan Coronavirus, china coronavirus, coronavirus, wuhan coronavirus.
The coronavirus continues to threaten the global drug supply line, with disruption to the US drug production pipeline from the …
Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows
March 6, 2020Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma
Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …
Lack of mental health treatment available for HIV patients in the UK
March 6, 2020Medical Communications AIDS, HIV, HIV AIDS, HIV treatment, HIV/AIDS
A cross-party group of MPs have said that those with HIV do not have access to adequate mental health treatment. …
Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer
March 6, 2020Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …
Indian regulators approve first drug for patients with NASH
March 6, 2020Medical Communications FDA Approval, India, Indian Pharma, drug approval
The Drug Controller General of India (DCGI) has approved the marketing application for Zydus Cadila’s saroglitazar to treat patients with …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
